Baretti, M <br/><br/>
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?  [electronic resource] 

 -  Cancer biology & therapy  08 2018 
 - 659-663 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article 
<br/><br/><label>ISSN: </label>1555-8576 
<br/><br/><label>Standard No.: </label>10.1080/15384047.2018.1450117  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Biomarkers<br/>Colorectal Neoplasms--drug therapy<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Humans<br/>Immunohistochemistry<br/>Liver Neoplasms--diagnosis<br/>Molecular Targeted Therapy<br/>Mutation<br/>Proto-Oncogene Proteins p21(ras)--genetics<br/>Tomography, X-Ray Computed<br/>Treatment Outcome